Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Nurix Therapeutics, Inc. (NRIX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 10-Q Quarterly Report for the period ended August 31, 2023
10/12/2023 8-K Quarterly results
07/13/2023 10-Q Quarterly Report for the period ended May 31, 2023
07/13/2023 8-K Results of Operations and Financial Condition  Interactive Data
Docs: "Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update Announced Phase 1b expansion cohorts for NX-2127 in non-Hodgkin’s lymphomas"
05/04/2023 8-K Quarterly results
04/13/2023 10-Q Quarterly Report for the period ended February 28, 2023
04/13/2023 8-K Quarterly results
Docs: "Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update Licensed to Gilead a new development candidate, NX-0479/GS-6791, a targeted protein degrader of IRAK4, resulting in a $20 million payment"
03/24/2023 ARS Form ARS - Annual Report to Security Holders:
03/24/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/24/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/13/2023 8-K Other Events  Interactive Data
02/24/2023 SC 13G Deep Track Capital, LP reports a 5.8% stake in Nurix Therapeutics, Inc.
02/14/2023 SC 13G/A Third Rock Ventures III, L.P. reports a 0.4% stake in Nurix Therapeutics, Inc.
02/14/2023 SC 13G/A BAKER BROS. ADVISORS LP reports a 10% stake in Nurix Therapeutics, Inc.
02/14/2023 SC 13G/A PRICE T ROWE ASSOCIATES INC reports a 6.9% stake in NURIX THERAPEUTICS INC
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G STATE STREET CORP reports a 5.3% stake in INITIAL FILING NURIX THERAPEUTICS INC
02/09/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/09/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
02/09/2023 8-K Quarterly results
Docs: "Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update Demonstrated NX-2127 overcomes BTK inhibitor resistance mutations and provides clinical benefit to patients with hematological malignancies"
02/09/2023 POSASR Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
02/08/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
01/25/2023 SC 13G/A BlackRock Inc. reports a 8.8% stake in Nurix Therapeutics, Inc.
01/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Nurix Therapeutics, Inc. presentation",
"Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities"
12/16/2022 8-K Quarterly results
12/12/2022 8-K Quarterly results
10/26/2022 8-K Quarterly results
10/06/2022 10-Q Quarterly Report for the period ended August 31, 2022
10/06/2022 8-K Quarterly results
09/14/2022 8-K Appointed a new director
Docs: "Nurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of Directors"
07/08/2022 8-K Quarterly results
07/08/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/08/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/07/2022 10-Q Quarterly Report for the period ended May 31, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy